Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.34 |
| ▸ | BCAT1 | P54687 | 5/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6135068 | 1.00 | SCN9A (0.35) | SCN9ABCL2L1MCL1BCAT1HDAC8 | |
| SCHEMBL6135001 | 0.91 | SCN9A (0.36) | SCN9ABCL2L1MCL1BCAT1HDAC8 | |
| SCHEMBL6135003 | 0.91 | SCN9A (0.36) | SCN9ABCL2L1MCL1BCAT1HDAC8 | |
| SCHEMBL6299326 | 0.89 | PPARG (0.40) | SCN9ABCAT1HDAC8HDAC6CYP2C9 | |
| SCHEMBL6299324 | 0.89 | PPARG (0.40) | SCN9ABCAT1HDAC8HDAC6CYP2C9 | |
| SCHEMBL6301054 | 0.87 | PTPN1 (0.48) | SCN9ABCL2L1MCL1PTPN1 | |
| SCHEMBL6306044 | 0.85 | PTGER4 (0.46) | BCL2L1MCL1BCAT1PTGER4 | |
| SCHEMBL6299366 | 0.82 | ALDH1A1 (0.40) | BCAT1HDAC8HDAC6KMT2A | |
| SCHEMBL6299371 | 0.82 | ALDH1A1 (0.40) | BCAT1HDAC8HDAC6KMT2A | |
| SCHEMBL6299045 | 0.82 | BCL2L1 (0.42) | BCL2L1MCL1BCAT1PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050197376-A1 | Concomitant drugs | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-09-08 | — | — | US | claimed |
| US-20050197376-A1 | Concomitant drugs | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-09-08 | — | — | US | disclosed |
| US-6911469-B2 | Sulfonamide compounds and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-28 | — | — | US | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-07-25 | — | — | US | disclosed |
| US-6348474-B1 | COMPOUNDS AS ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0995742-A1 | SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099212-A1 | For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity | PDE2A, PDE3A, PDE12 | SCN9A 990/4885BCL2L1 2810/4885MCL1 4681/4885 |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | PDE2A, PDE3A, PYGM | SCN9A 1174/4885BCL2L1 2737/4885MCL1 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.